NPPA fixes retail price of 40 formulations
Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 40 new drugs, including those used to treat high blood pressure, type 2 diabetes, certain types of stomach cancer, bacterial infections, and those used to relieve pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, muscle pain, bone pain, and joint pain.
These include Akums Drugs, Cipla's Metoprolol Succinate (as Extended Release), Chlorthalidone, and Telmisartan fixed-dose combination tablets, Akums Drugs, Apex Laboratories' Mefenamic Acid and Paracetamol Oral Suspension, Windlas Biotech, Micro Lab's Nebivolol Hydrochloride and Telmisartan Tablet, Ahlcon Parenterals, SunPharmaceutical's Budesonide Nebuliser Suspension BP 0.5mg/2m, and Skymap Pharmaceuticals' Clopidogrel and Aspirin Tablets.
For more details, check out the link given below:
NPPA Fixes Retail Price Of 40 Formulations Including Dapagliflozin-Metformin FDC
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.